Roche鈥檚 US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
Roche's (OTCQX:RHHBY) subsidiary Genentech has initiated construction of a $700 million manufacturing facility in Holly Springs, North Carolina. The 65,000 m虏 facility, set to be operational by 2029, represents Genentech's first East Coast manufacturing site and is part of Roche's larger $50 billion investment in US operations.
The strategic facility will focus on producing next-generation metabolic medicines, including obesity treatments, and is expected to create more than 1,900 jobs. Located on a 400,000 m虏 lot with expansion potential, the site was chosen for its skilled workforce, academic institutions, and proximity to other life science companies.
Genentech, controllata di Roche (OTCQX:RHHBY), ha avviato i lavori per costruire un impianto di produzione del valore di $700 milioni a Holly Springs, North Carolina. La struttura coprir脿 65.000 m虏 e, prevista in funzione entro il 2029, sar脿 il primo sito di produzione di Genentech sulla Costa Est e rientra nel pi霉 ampio piano di investimenti di $50 miliardi di Roche negli Stati Uniti.
Il nuovo impianto sar脿 destinato alla produzione di farmaci metabolici di nuova generazione, compresi trattamenti per l'obesit脿, e dovrebbe generare oltre 1.900 posti di lavoro. Situato su un'area di 400.000 m虏 con possibilit脿 di espansione, il sito 猫 stato scelto per la disponibilit脿 di personale qualificato, la vicinanza ad istituzioni accademiche e ad altre aziende nel settore delle scienze della vita.
Genentech, subsidiaria de Roche (OTCQX:RHHBY), ha comenzado la construcci贸n de una planta de fabricaci贸n de $700 millones en Holly Springs, Carolina del Norte. La instalaci贸n, de 65.000 m虏 y prevista para entrar en servicio en 2029, ser谩 el primer centro de producci贸n de Genentech en la Costa Este y forma parte de la inversi贸n total de $50.000 millones de Roche en Estados Unidos.
La planta se centrar谩 en producir medicamentos metab贸licos de pr贸xima generaci贸n, incluidos tratamientos contra la obesidad, y se espera que cree m谩s de 1.900 puestos de trabajo. Ubicada en un terreno de 400.000 m虏 con capacidad de expansi贸n, la localizaci贸n se eligi贸 por su mano de obra cualificada, la cercan铆a a instituciones acad茅micas y a otras empresas de ciencias de la vida.
搿涤妶(翱罢颁蚕齿:搁贬贬叠驰)鞚� 鞛愴殞靷� 鞝滊劏韰�(骋别苍别苍迟别肠丑)鞚� 雲胳姢旌愲·霛检澊雮� 頇�毽� 鞀ろ攧毵侅姢鞐� 7鞏� 雼煬 攴滊鞚� 鞝滌“鞁滌劋 瓯挫劋鞚� 鞁滌瀾頄堨姷雼堧嫟. 鞚� 鞁滌劋鞚� 65,000 m虏 攴滊搿� 2029云� 臧�霃欖潉 氇╉憸搿� 頃橂┌, 鞝滊劏韰嶌潣 斓滌磮 霃欗暣鞎� 鞝滌“旮办搿� 搿滌妶鞚� 氙戈淡 雮� 500鞏� 雼煬 韴瀽 瓿勴殟鞚� 鞚柬櫂鞛呺媹雼�.
頃措嫻 鞁滌劋鞚� 牍勲 旃橂鞝滊ゼ 韽暔頃� 彀劯雽� 雽�靷� 歆堩櫂 鞚橃暯頀� 靸濎偘鞐� 欷戩爯鞚� 霊愲┌, 1,900氇� 鞚挫儊鞚� 鞚检瀽毽ゼ 彀届稖頃� 瓴冹溂搿� 鞓堨儊霅╇媹雼�. 400,000 m虏 攵�歆�鞐� 頇曥灔 鞐臧� 鞛堨溂氅�, 靾欕牗霅� 鞚鸽牓, 頃欔硠鞕�鞚� 攴检爲靹�, 雼るジ 靸濍獏瓿柬暀 旮办梾霌り臣鞚� 鞚胳爲靹� 霌膘澊 攵�歆� 靹犾爼 鞚挫湢搿� 昙巾様鞀惦媹雼�.
Genentech, filiale de Roche (OTCQX:RHHBY), a lanc茅 la construction d'une usine de production d'une valeur de 700 millions de dollars 脿 Holly Springs, en Caroline du Nord. L'installation de 65 000 m虏, qui devrait 锚tre op茅rationnelle d'ici 2029, sera le premier site de production de Genentech sur la c么te Est et s'inscrit dans le cadre du plan d'investissement de 50 milliards de dollars de Roche aux 脡tats-Unis.
Cette usine strat茅gique se consacrera 脿 la fabrication de m茅dicaments m茅taboliques de nouvelle g茅n茅ration, notamment des traitements contre l'ob茅sit茅, et devrait permettre de cr茅er plus de 1 900 emplois. Le site, situ茅 sur un terrain de 400 000 m虏 offrant des possibilit茅s d'expansion, a 茅t茅 choisi pour la qualit茅 de sa main-d'艙uvre, la proximit茅 d'茅tablissements acad茅miques et d'autres entreprises des sciences de la vie.
Genentech, eine Tochtergesellschaft von Roche (OTCQX:RHHBY), hat mit dem Bau einer 700 Millionen Dollar teuren Produktionsanlage in Holly Springs, North Carolina begonnen. Die 65.000 m虏 gro脽e Anlage soll bis 2029 in Betrieb gehen und ist Genentechs erster Produktionsstandort an der Ostk眉ste; sie ist Teil der gr枚脽eren 50 Milliarden Dollar-Investition von Roche in den USA.
Die strategische Anlage wird sich auf die Herstellung von Medikamenten f眉r Stoffwechselerkrankungen der n盲chsten Generation, einschlie脽lich Adipositas-Behandlungen, konzentrieren und voraussichtlich mehr als 1.900 Arbeitspl盲tze schaffen. Das Gel盲nde umfasst 400.000 m虏 mit Ausbaupotenzial und wurde wegen der qualifizierten Arbeitskr盲fte, der N盲he zu akademischen Einrichtungen und anderen Life-Sciences-Unternehmen ausgew盲hlt.
- Investment of $700 million in new manufacturing facility demonstrates strong commitment to US market
- Creation of over 1,900 new jobs in North Carolina
- Strategic expansion into East Coast manufacturing enhances supply chain resilience
- Facility designed for future expansion with 400,000 m虏 lot space available
- Part of larger $50 billion investment commitment in US operations
- Long timeline to operational status - facility not expected to be functional until 2029
- Significant capital expenditure may impact short-term financial flexibility
- The
$700 million project is part of Roche鈥檚$50 billion investment in US manufacturing, infrastructure and R&D. - The facility will create more than 1,900 jobs and support the production of next-generation metabolic medicines, including treatments for obesity
- These investments underscore Roche鈥檚 commitment to innovative manufacturing, designed to bring life-changing treatments to patients faster
Basel, 25 August 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today broke ground on its newest US manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech鈥檚 first manufacturing facility on the East Coast. The 65,000 m虏 facility is strategically designed to support production of the company鈥檚 future portfolio of metabolic medicines, including next-generation treatments for obesity.
Genentech鈥檚 initial investment in North Carolina is estimated at more than
Roche Group CEO Thomas Schinecker:
鈥淚 am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments. This
The company selected Holly Springs in North Carolina, a growing hub for biopharmaceutical innovation, for its highly skilled local workforce, strong academic institutions and proximity to other leading life science companies.
The new facility is expected to be completed and operational by 2029, incorporating modern biomanufacturing technologies, as well as advanced automation and digital capabilities. The 400,000 m虏 lot includes space for future expansion.
Designed for high-volume, efficient, and sustainable production, the new facility will increase Roche鈥檚 manufacturing capacity and enhance supply chain resilience. It complements Roche鈥檚 manufacturing sites around the world, including in Europe and Switzerland, to efficiently serve patients where they are.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world鈥檚 largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche鈥檚 business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit .
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: [email protected]
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Kirti Pandey Phone: +49 172 6367262 | Yvette Petillon Phone: +41 79 961 92 50 |
| Dr Rebekka Schnell Phone: +41 79 205 27 03 | 听 |
Attachment
FAQ
How much is Roche investing in the new North Carolina manufacturing facility?
How many jobs will Roche's new North Carolina facility create?
When will Roche's new Holly Springs manufacturing facility be operational?
What types of medicines will be produced at Roche's new North Carolina facility?
How large is Roche's new manufacturing facility in Holly Springs?
